Regulation of atrial natriuretic peptide, thromboxane and prostaglandin production by androgen in elderly men with coronary heart disease.
Several recent observations suggest that atrial natriuretic peptides (ANP) can modulate steroidogenesis in isolated rat Leydig cells and in young men. Other observations suggest that catechol estrogen can inhibit prostaglandin (PGI2) release in the endothelium, and we had found that androgen can relieve angina pectoris and improve myocardial ischemia in elderly men with coronary heart disease (CHD), possibly through relieving coronary artery smooth muscle spasm. Because ANP and PGI2 are vasoactive peptides which regulate vasomotion, there must be an interaction between steroidogenesis hormones and vasoactive peptides. We evaluated the effects of androgen (Sustanon 250) administration on plasma ANP, PGI2 and thromboxane (TXA2) levels in elderly men with CHD. Thirty 60-75-year-old men with CHD received 250 mg (1 ml) Sustanon 250 injection, and 30 age- and sex-matched CHD patients received 1 ml saline. Plasma ANP, PGI2, TXA2, estradiol (E2) and testosterone (T) were determined before injection and 3 weeks thereafter. The results showed that Sustanon 250 administration increased plasma ANP levels, decreased TXA2 and increased PGI2 levels significantly, and thereby improved the TXA2/PGI2 imbalance in CHD patients (all P < 0.01). Meanwhile, serum T levels rose (P < 0.01), but E2 levels remained unchanged, and thus the E2/T ratio decreased (P < 0.05). Our findings demonstrate that androgen exerts its regulatory role by altering plasma ANP levels and the TXA2/PGI2 ratio.
Beijing Red Cross Chaoyang Hospital.
S
S
Wu
X
X
Weng
D015121:6-Ketoprostaglandin F1 alpha / Q000097:blood*; D000368:Aged; D009320:Atrial Natriuretic Factor / Q000097:blood*; D003692:Delayed-Action Preparations; D004338:Drug Combinations; D004958:Estradiol / Q000097:blood; D006801:Humans; D008297:Male; D008875:Middle Aged; D009203:Myocardial Infarction / Q000097:blood* / Q000188:drug therapy; D013739:Testosterone / Q000031:analogs & derivatives* / Q000097:blood / Q000627:therapeutic use; D013929:Thromboxane B2 / Q000097:blood*
D003692:Delayed-Action Preparations; D004338:Drug Combinations; D013739:Testosterone; D004958:Estradiol; D013929:Thromboxane B2; D015121:6-Ketoprostaglandin F1 alpha; D009320:Atrial Natriuretic Factor